Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics
GlobeNewswire - Thu Apr 10, 6:01AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Patent and Trademark Office (PTO) has issued Patent No. 8,691,573 entitled "Stem Cell Cultures." The newly issued patent claims a class of small molecule inhibitors of Rho-associated kinase (ROCK) that are crucial to the therapeutic application of human induced pluripotent stem cells (hiPSCs). Modulators belonging to the patented class have been shown to be necessary for the high-throughput derivation of transgene-free hiPSCs, and for the maintenance, survival and genomic stability of hiPSCs in culture. Fate Therapeutics holds an exclusive license from The Scripps Research Institute (TSRI) to the patent in all commercial fields.
Fate Therapeutics (FATE) Falls: Stock Goes Down 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:37AM CDT
Fate Therapeutics has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Fate Reports In-Line Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:28PM CDT
Share price of Fate Therapeutics (FATE) gained 10.3% after the company released fourth quarter earnings but lost 4.0% in the next trading session. Overall, shares gained 6.15% following the fourth quarter results.
Fate Therapeutics adds Dr Robert S. Epstein to board
M2 - Tue Mar 18, 5:41AM CDT
Biopharmaceutical company Fate Therapeutics (NasdaqGM:FATE) reported on Monday the election of Dr Robert S. Epstein, MD to its board of directors.
Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 17, 3:01PM CDT
Phase 2 PUMA Study of PROHEMA(R) Initiated - Interim Data Expected in 2H14
Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.
Fate Therapeutics' Prohema in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 10:50AM CDT
Fate Therapeutics' Prohema enters phase II study
Fate Therapeutics enrolls first patient in Phase 2 clinical trial of PROHEMA under PUMA study for treating hematologic malignancies
M2 - Thu Mar 13, 4:25AM CDT
Biopharmaceutical company Fate Therapeutics (NasdaqGM:FATE) disclosed on Wednesday the admission of the first patient in its "PUMA" study under its Phase 2 clinical trial of PROHEMA in patients undergoing hematopoietic stem cell (HSC) transplantation for the treatment of hematologic malignancies.
Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies
GlobeNewswire - Wed Mar 12, 6:01AM CDT
First Patient Enrolled in PUMA Study
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2013 Financial Results on March 17, 2014
GlobeNewswire - Tue Mar 11, 6:02AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Monday, March 17, 2014, at 5:00 p.m. EDT to report its fourth quarter and full year 2013 financial results and provide a corporate update.
Fate Therapeutics Announces Publication of Its Proprietary Stem Cell Modulation Platform for Developing iPSC-Based Regenerative Therapeutics
GlobeNewswire - Thu Mar 06, 6:09AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the publication of an article in the journal Stem Cell Reports by Fate scientists demonstrating high-throughput derivation of human induced pluripotent stem cells (hiPSCs) that exhibit characteristics necessary for therapeutic application. The publication describes the use of the Company's hiPSC platform, consisting of stage-specific cell culture systems, to enable rapid, parallel derivation of hiPSC clones and their subsequent expansion as transgene-free, single cells in culture. The Company's proprietary combinations of small molecule modulators, which include ROCK, GSK3 and MEK pathway inhibitors, used in the culture systems were found to be critical in promoting characteristics of the ground state of pluripotency including pluripotent culture stability, homogeneity and survival.
Fate Therapeutics Observes Rare Disease Day 2014
GlobeNewswire - Fri Feb 28, 6:01AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, is joining the Muscular Dystrophy Association (MDA) and other advocacy organizations around the world today to observe Rare Disease Day.
Fate Therapeutics to Present at Upcoming March Conferences
GlobeNewswire - Thu Feb 27, 6:45AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the company's programs and outlook at the following March conferences:
Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R)
GlobeNewswire - Wed Feb 26, 6:03AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the release of new data on the observed effects of ex vivo pharmacologic modulation on CD8+ T cells and immune reconstitution from its previously-completed Phase 1b clinical trial of PROHEMA (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) in adult patients undergoing hematopoietic stem cell (HSC) transplantation for hematologic malignancy (the ProHema-01 trial). Researchers affiliated with Harvard Medical School performed an analysis of the CD8+ T cell compartment using patient samples from the ProHema-01 trial. At Day 100, subjects who received PROHEMA and an unmanipulated cord blood unit (n=12) showed a two-fold increase in the percentage of naïve and early memory T cell fraction within the CD8+ T cell compartment as compared to subjects who received two unmanipulated cord blood units (n=9). These naïve and early memory CD8+ T cell populations are believed to play a key role in promoting immune reconstitution and viral immunity following cord blood transplantation. These findings were recently published in Blood Cancer Journal (Li, L. et. al. Blood Cancer Journal 2014).
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Marketwire - Thu Jan 30, 6:38AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, is pleased to announce that its Board of Directors has elected Dr. Calvin R. Stiller as Chairman of the Board. Dr. Stiller has been a member of the Board since July 2011 and served as Lead Director and Chair of the Governance and Nominating Committee.
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 02, 12:34PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Nasdaq stocks posting largest volume decreases
AP - Fri Dec 27, 4:59PM CST
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
Global Bone Degeneration Market Report 2013
M2 - Mon Dec 09, 6:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/94cktb/bone_degeneration) has announced the addition of the "Global Bone Degeneration Market Report 2013" report to their offering. This report provides information on the therapeutic development for Bone Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Degeneration. The analysis is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Bone Degeneration. - A review of the Bone Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bone Degeneration. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bone Degeneration pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Table of Contents List of Tables List of Figures Introduction REPORT COVERAGE Bone Degeneration Overview Therapeutics Development Companies Involved in Bone Degeneration Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Amgen Inc. - Cell Therapeutics, Inc. - Calzada Limited - Alethia Biotherapeutics Inc. - Fate Therapeutics, Inc. - Se-cure Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/94...generation
Market Research: Lysosomal Storage Disorder - Pipeline Review, H2 2013
M2 - Wed Nov 20, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/j39q2v/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H2 2013" report to their offering. 'Lysosomal Storage Disorder - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lysosomal Storage Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder. Scope - A snapshot of the global therapeutic scenario for Lysosomal Storage Disorder. - A review of the Lysosomal Storage Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lysosomal Storage Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Sangamo BioSciences, Inc. BioMarin Pharmaceutical Inc. Neuralstem, Inc. Amicus Therapeutics, Inc. Cytomedix, Inc. AngioChem Inc. Zymenex A/S Synageva BioPharma Corp. Fate Therapeutics, Inc. REGiMMUNE Corporation For more information visit http://www.researchandmarkets.com/research/j3...al_storage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.